afatinib + temozolomide

Afatinib (BIBW 2992) is an orally bioavailable small molecule that irreversibly inhibits the receptor tyrosine kinases of the ErbB family, including epidermal growth factor receptor (EGFR), HER2, and HER4. It is primarily developed for non-small cell lung cancer but has also been investigated in combination with other therapies for glioblastoma multiforme (GBM)[3][4]. Temozolomide (TMZ) is an oral alkylating agent that methylates DNA at several sites, leading to DNA damage and tumor cell death. It is a standard chemotherapeutic agent for GBM[1][5][8]. The combination of afatinib and temozolomide has been studied in preclinical and early clinical settings for synergistic effects against GBM cells expressing EGFR mutations or overexpression[1][4].

Other names

afatinib dimaleatetemozolomide